

Brigida Anna Maiorano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/202268/publications.pdf>

Version: 2024-02-01

20
papers

308
citations

932766

10
h-index

940134

16
g-index

22
all docs

22
docs citations

22
times ranked

351
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. <i>Cancers</i> , 2019, 11, 1055.	1.7	40
2	Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4438.	1.7	40
3	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 232.	1.3	31
4	Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5447.	1.8	29
5	Efficacy of immune checkpoint inhibitors in different types of melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4-13.	1.4	19
6	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. <i>Vaccines</i> , 2021, 9, 623.	2.1	17
7	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2021, 14, 476.	1.7	16
8	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15
9	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3871.	1.8	14
10	Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 195-205.	1.5	12
11	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. <i>Cancer Treatment Reviews</i> , 2022, 105, 102373.	3.4	12
12	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. <i>Biomedicines</i> , 2022, 10, 411.	1.4	11
13	Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. <i>Seminars in Cancer Biology</i> , 2022, 86, 997-1007.	4.3	8
14	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 83-86.	2.0	7
15	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients'™ Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.	1.2	7
16	How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2022, 12, 844801.	1.3	7
17	Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. <i>Immunotherapy</i> , 2022, 14, 65-75.	1.0	6
18	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. <i>Protein and Peptide Letters</i> , 2020, 27, 1276-1287.	0.4	2

#	ARTICLE	IF	CITATIONS
19	First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 365.	1.5	1
20	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	1.3	1